Rolapitant

Rolapitant is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.

Rolapitant is a selective neurokinin-1 (NK1) receptor antagonist primarily used in the pharmaceutical industry for the prevention of chemotherapy-induced nausea and vomiting (CINV). It is administered as part of antiemetic therapy in oncology, often in combination with other agents such as serotonin (5-HT3) antagonists and corticosteroids. Rolapitant is also used in clinical research to investigate NK1 receptor pathways, central nervous system pharmacology, and potential applications in other disorders involving substance P signaling.

The benefits of rolapitant include its long half-life, high receptor selectivity, and potent antiemetic effect, which allows for single-dose administration per chemotherapy cycle. Its selective NK1 receptor antagonism reduces the incidence of delayed nausea and vomiting without significantly affecting other neurotransmitter systems, minimizing side effects. Additionally, its pharmacokinetic profile supports predictable efficacy and convenience for patients, improving adherence and quality of life during chemotherapy.

Rolapitant is a targeted NK1 receptor antagonist with applications in preventing chemotherapy-induced nausea and vomiting and in pharmacological research. Its benefits include potent, selective, and long-lasting antiemetic effects, making it a critical agent for supportive care in oncology and a valuable tool in studies of NK1 receptor-mediated pathways.

Previous

Pregnenolone Acetate丨CAS 1778-02-5

Next

Glutathione丨CAS 70-18-8